Premium
Surgical management of rectal gastrointestinal stromal tumors
Author(s) -
Tielen Ronald,
Verhoef Cornelis,
van Coevorden Frits,
Reyners Anna K.,
van der Graaf Winette T.A.,
Bonenkamp Johannes J.,
van Etten Boudewijn,
de Wilt Johannes H.W.
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23223
Subject(s) - medicine , gist , rectum , imatinib , surgery , stromal tumor , retrospective cohort study , imatinib mesylate , stromal cell , myeloid leukemia
Background Five percent of gastrointestinal stromal tumors (GISTs) are primarily localized in the rectum. We analyzed the outcome of multimodality treatment for rectal GIST in a multicenter retrospective series. Methods All surgically treated patients with a rectal GIST were identified from four specialized centers in the Netherlands. Primary endpoints were disease‐free survival (DFS) and overall survival (OS). Results Thirty‐two patients (22 men and 10 women) with rectal GISTs were identified. Twenty‐two patients received imatinib before surgery for a median of 9 (range 2–53) months (Group 1). Ten patients received no imatinib because of small tumor size or lack of availability (Group 2). Median tumor size before treatment was 9.3 (range 6–17) cm in Group 1 and median 6 (range 4–14) cm in Group 2. A complete resection was possible in 17/22 (77%) patients in Group 1 versus 7/10 (70%) in Group 2. Median DFS was not reached in Group 1, while it was 36 months in Group 2. Median OS was not reached in both groups. Conclusions Preoperative imatinib leads to downsizing of the tumors in Group 1. However, it has not led to less extensive surgery. The DFS is longer in patients treated with pre‐ and post‐operative imatinib, without an effect on OS. J. Surg. Oncol. 2013;107:320–323. © 2012 Wiley Periodicals, Inc.